RxDoctor Payments Data

Gary Schillhammer, MD

Family Medicine · Darrington, WANPI 1396735437

Payments from drug & device makers

$308in general payments, 2019–2025

Across 12 payments — averaging $25.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$158
  • Sanofi-aventis U.S. LLC$37
  • Biohaven Pharmaceuticals, Inc.$25
  • Sanofi Pasteur Inc.$22
  • E.r. Squibb & Sons, L.L.C.$21
  • Indivior Inc.$18
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$308 in reported general payments places this provider in the 70th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$4,945
Medicare patients
71
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$76,209
EliquisApixaban50$51,556
OzempicSemaglutide24$41,578
XareltoRivaroxaban28$41,438
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$28,388
Combivent RespimatIpratropium/Albuterol Sulfate18$20,132
JanuviaSitagliptin Phosphate11$13,661
Soliqua 100-33Insulin Glargine/Lixisenatide11$8,970
Emgality PenGalcanezumab-Gnlm11$7,975
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,543
Albuterol Sulfate HfaAlbuterol Sulfate147$4,915
SymbicortBudesonide/Formoterol Fumarate13$3,666
Wixela InhubFluticasone Propion/Salmeterol18$3,652
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,150
Gabapentin120$2,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sanofi-aventis U.S. LLCSoliqua 100-33$37$8,97011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Darrington

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →